BridgeBio Pharma (BBIO) Non-Current Deffered Revenue (2023 - 2026)

BridgeBio Pharma has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $11.8 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 32.74% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.8 million (down 32.74% YoY) and the FY2025 annual result came in at $13.1 million, down 23.49% from the prior year.
• Non-Current Deffered Revenue declined to $11.8 million in Q1 2026 per BBIO's latest filing, from $13.1 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $19.9 million in Q1 2024 and troughed at $3.7 million in Q4 2023.
• A 4-year average of $14.6 million and a median of $15.8 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2024 and 2026: Non-Current Deffered Revenue soared 358.68% in 2024, then plunged 32.74% in 2026.
• Over 4 years, Non-Current Deffered Revenue stood at $3.7 million in 2023, then jumped by 358.68% to $17.1 million in 2024, then slipped by 23.49% to $13.1 million in 2025, then fell by 9.97% to $11.8 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $11.8 million, $13.1 million, and $13.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.